The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
_256_384.jpg)
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
The company plans to expand its portfolio in regulated markets aggressively
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The first clinical trial is expected to commence in early 2022 both in Europe and the US
Subscribe To Our Newsletter & Stay Updated
